INTRODUCTION

76
Urothelial bladder cancer (UBC) is the fifth most common cancer in Western societies, 77 accounting for 10,000, 69,000 and 180,000 new cases per year in the UK, USA and EU [1] , 78 respectively. The global incidence of the disease is rising reflecting patterns of cigarette 79 smoking and occupational carcinogen exposure [2] , the most common aetiological factors 80 [1] . There has been little improvement in the outcome for UBC patients since the 1980s, 81 reflecting complex diagnostic pathways and treatment regimens, and a lack of therapeutic 82 advances [3] . Given these constraints, much attention has been paid to reducing delays in 83 presentation [4] , diagnosis and treatment [5] . 84 
85
For UBC the relationship between time to diagnosis and treatment, and disease-specific 86 survival is complex [6] [7] [8] [9] ; many tumours are indolent, for which delay in diagnosis does not 87 alter survival [10] , and outcomes from aggressive UBCs are multifactorial [6] [7] [8] [9] . In addition 88 to delays in healthcare pathways, disease biology (reflected by stage, grade and tumour 89 characteristics [11;12] ) and patient-specific factors are important. The latter reflect 90 aetiological agent exposures (e.g. smoking is more common in males) [9;13;14] , gender-91 specific misdiagnoses (e.g. females are more likely to be incorrectly diagnosed with infection 92 [15] ) [1;16;17] , and potential differences in the molecular pathogenesis of male and female 93 UBC [18] . 94 
95
To obtain a clearer understanding of factors affecting outcomes in UBC, we have followed a 96 large cohort of prospectively recruited patients since 1991 [9] . This population represents 97 85% of new cases of UBC arising over an 18month period within the West Midlands region of the UK [9] . Here we report long-term outcomes and investigate the influence of gender, 99 carcinogen exposure and pathway delays in this cohort. Figure 1a) . Here we report 17-year outcomes from newly-diagnosed cases of UBC within a large 232 geographic region in the UK. We have updated an initial report [9] , and now have most 233 cases (75%) followed until death. We are thus able to examine the complex interaction 234 between the tumour, patient gender, carcinogen exposures, pathway delays, and mortality. 235 We identified in univariate and competing risks analysis that many of these factors were Other Cancer 65 (25) 31 (20) 2 (14) 2 (18) 100 (23) 5 (17) 12 (11) 10 (14) 2 (17) 29 (13) 24 (8) (24) 199 (28) 184 (25) 187 (27) 193 (27) 178 (24) 188 (26) 184 (26) 168 (23) 203 (28) Tumour stage pTa 658 340 (54) 314 (48) 345 (52) 309 (50) 312 (51) 342 (51) 321 (49) 333 (52) 320 (50) 334 (52) pT1 291 140 (22) 149 (23) 140 (21) 149 (24) 131 (21) 158 (24) 148 (23) 142 (22) 146 (23) 143 (22) T2-T4 351 154 (24) 186 (29) 176 (27) 164 (26) 168 (27) 172 (26) 181 (28) 161 (25) 179 (28) 161 (25 (24) 142 (22) 138 (23) 140 (23) 140 (22) 138 (22) 142 (23) 126 (20) 
SUPPLEMENTARY METHODS
To assess the competing risks of death in our cohort, we first used a non-parametric test to assess the equality between groups by calculating the cumulative incidence function (CIF) as described by Scrucca et al. [1] . Comparison of specific CIFs was performed using Gray's test [2] . We then extended our analysis to investigate the effects of other covariates (stage at diagnosis, tumour grade, gender, smoking status, occupational exposure risk and age group at diagnosis), present in our data on the CIF. We constructed flexible parametric models using the user written Stata command stpm2 in order to calculate the cause-specific hazard for each cause and for each covariate of interest [3] . Gender and cause of death were modeled as time-varying covariates. We used information from the Akaike Information Criterion (AIC) and Bayesian Information Criterion (BIC) for model selection. Post-estimation we applied the user written stpm2cif command [4] , so that the cumulative incidence function for each model of interest could be derived and graphed.
LEGENDS
Supplementary Table 1:
Occupations with known or suspected exposure to urothelial carcinogens, and chemicals implicated in urothelial carcinogenesis. These data were utilised by the assessors to assign risk of occupational exposure.
Supplementary Table 2:
Survival by delay times stratified for tumour stage. 
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